Nicotine replacement therapy for smoking cessation in the "real world"

Thorax

Volumn 62, Issue 11, 2007, Pages 930-931

  Shiffman, Saul ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE;

BEHAVIOR THEORY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; EDITORIAL; HUMAN; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME;

HUMANS; NICOTINE; NICOTINIC AGONISTS; SMOKING; SMOKING CESSATION;

EID: 36048959900     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.081919     Document Type: Editorial

References (18)

1. West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study. Thorax 2007;62:998-1002.
2. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002;288:1260-4.
3. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. In: Cochrane Library, Issue 1. Chichester: John Wiley & Sons Ltd, 2004.
4. Hughes JR, Shiffman S, Callas P, et al. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 2003;I:21-7.
5. Bauer MS, Williford WO, Dawson EE, et al. Principles of effectiveness trials and their implementation in VA Cooperative Study #430: reducing the efficacy-effectiveness gap in bipolar disorder. J Affect Disord 2001;67:61-78.
6. Shiffman S, Brockwell S, Pillitteri JL, et al. Quit attempts and use of smoking cessation treatments in the USA: an analysis of the 2003 current population survey. Poster presented at the Annual Meeting of the Society for Research on Nicotine and Tobacco; February 2007, Austin, Texas, USA.
7. White P, Watt J. Tobacco control in London: facts and issues. London: SmokeFree London, 2002.
8. Gilpin E, Pierce JP. Measuring smoking cessation: problems with recall in the 1990 California Tobacco Survey. Cancer Epidemiol Biomarkers Prev 1994;3:613-7.
9. Shiffman S, Di Marino ME, Sweeney CT. Characteristics of selectors of nicotine replacement therapy. Tob Control 2005;14:346-55.
10. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983;2:267-71.
11. Strecher VJ, Shiffman S, West R. Randomized controlled trial of a web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction 2005;100:682-8.
12. Cokkinides VE, Ward E, Jemal A, et al. Under-use of smoking-cessation treatments: Results from the National Health Interview Survey, 2000. Am J Prev Med 2005;28:119-22.
13. Zhu S, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med 2002;347:1087-93.
14. Shiffman S, Rolf CN, Hellebusch SJ, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction 2002;97:505-16.
15. Shiffman S, Hughes JR, Pillitteri JL, et al. Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population-based sample. Tob Control 2003;12:310-6.
16. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction 2007;102:809-14.
17. Shiffman S, Brockwell S, Gitchell J, et al. Wearing nicotine patches continuously for three weeks during a cessation attempt improves short-term efficacy. Poster presented at the Annual Meeting of the Society for Research on Nicotine and Tobacco; February 2007, Austin, Texas, USA.
18. Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? Nicotine Tob Res 2004;6(Suppl 3):S303-10.